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defined?” and “How do we define 
the burden of skin disease?” After all, 
many of the diseases we dermatolo-
gists treat are poorly defined or ambig-
uously classified (or both). Many of our 
measures of clinical success are sub-
jective or captured by “soft” quality-
of-life scales, rather than “hard” life-
or-death outcomes on which fields like 
cardiology or oncology can rely.
The workshop participants recom-
mended the development of “novel 
approaches to defining and evaluating 
the burden of skin disease,” particu-
larly in the areas of cost-effectiveness 
assessment and quality-of-life evalua-
tion (Qureshi et al., 2004). They also 
called for the development of a con-
sensus on the classification of skin 
diseases, so that prospective studies 
on patients who are homogeneous 
(from a disease-classification perspec-
tive) could be performed (Qureshi et 
al., 2004).
As Dr. Freedberg and the other 
participants realized, an effort to 
understand how skin disease affects 
the public is not merely of academic 
interest. It has serious economic and 
policy implications. How much ben-
efit would we gain from spending a 
dollar treating, or researching, a given 
skin disease? Or would we gain more 
by spending that dollar on another 
skin (or non-skin) disease? Ultimately, 
these are questions whose answers 
will affect us, as dermatologists, and 
— more importantly — our patients 
living with skin disease.
With the well-being of patients ulti-
mately at stake, it’s no surprise that Dr. 
Freedberg was selected — and that he 
agreed — to lead a workshop that con-
tributed significantly to the field of pop-
ulation-based sciences in dermatology.
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The accompanying vignettes about 
Irwin Freedberg as the “organization 
man” are written by three individuals 
who both worked with him and closely 
observed his unique organizational and 
interpersonal skills. The vignettes are 
an acknowledgment of our respect and 
gratitude to this remarkable teacher, 
leader, and mentor. A great many of the 
people reading this brief remembrance 
essay will have known Irwin Freedberg, 
and therefore nothing we write will be 
new to them; but what a privilege it is 
for us to remember the contributions of 
this exceptional man to any organiza-
tion of which he was a part. Following 
are brief thoughts from the three of us 
on “Irwin the organization man.”
Stephen B. Webster, colleague: Irwin 
was a mentor to all of us, with wise 
counsel and support concerning any 
situation we might discuss with him. In 
the same manner, Irwin was always a 
mentor to the organizations with which 
he worked, and he was active in many 
organizations. As Irwin cared about his 
students and colleagues, he cared about 
the organizations of which he was a 
part. He could see the broad picture, 
and he could suggest the best course for 
the organization, always with the great-
est tact and sensitivity to its particular 
environment or time frame.
I served with Irwin in many organi-
zations, and he was active in so many 
it is impossible to cover them all; but I 
Correspondence: Dr. Stephen B. Webster, Gundersen Lutheran Medical Center, 1900 South Avenue, 
La Crosse, Wisconsin 54601, USA. Email: sbwebste@gundluth.org
especially remember his work with the 
American Board of Dermatology. As 
its president, his sincere concern and 
interest in the resident dermatologist 
were so apparent as he dealt with the 
many issues and challenges facing the 
Board in its mission of certifying der-
matologists. He was fully aware of the 
responsibility of the Board to assure 
the public that its diplomats have the 
training and background to provide the 
highest standard of care for patients 
with cutaneous diseases. At the same 
time he was always cognizant of the 
need to respond to and to support 
candidates seeking certification. Irwin 
was always at his best in a one-on-one 
situation. When he spoke with a candi-
date, that candidate felt, almost intui-
tively, that Irwin had a special interest 
in his or her professional life. Again, as 
he was a mentor to so many in the edu-
cational world, he was also a mentor 
to the American Board of Dermatology 
in its “certifying world.”
Irwin’s ability to present an honest 
and sincere interest in problems relat-
ing to medicine was also in strong evi-
dence as he served as a delegate to the 
American Medical Association from the 
Society for Investigative Dermatology. 
When Irwin spoke to delegates, either 
singly or in a group, he was listened to 
with respect. Irwin always represented 
the highest ethical and professional stan-
dards for our specialty of dermatology. 
Again, Irwin Freedberg was a mentor to 
us all in dermatology, and as he repre-
sented dermatology, he was a mentor to 
all of medicine.
Bradford Claxton, Executive Director, 
American Academy of Dermatology, 
1975–2000:
I first met Irwin Freedberg during the 
1978 debate regarding the publica-
tion of the Journal of the American 
Academy of Dermatology. At that time 
Dr Freedberg argued that there was no 
need for another dermatological publi-
cation. As was typical of Dr Freedberg’s 
correctness, he stated to the audience 
that he was the current editor of the 
Journal of Investigative Dermatology. 
This statement of potential conflict pre-
dated, by many years, the Academy’s 
requirement for disclosure. A few years 
later when Irwin and I were on a joint 
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committee together, he made a point to 
tell me that he was wrong in his assess-
ment of the need for the Journal of the 
American Academy of Dermatology. I 
recount this story because it speaks of 
his essence, his character and integrity 
— a person willing to listen and, when 
appropriate, change his opinion.
I next had the opportunity to work 
with Irwin when he was appointed to 
the Council on Government Liaison 
(currently the Commission on Health 
Policy) of the American Academy of 
Dermatology. At that time the Academy 
was shifting its Washington presence 
from one of monitoring to a more pro-
active role in the socioeconomic arena. 
Irwin, whose background was in aca-
demic and research issues, studied the 
effect of government’s involvement in 
the practice of medicine and became 
one of the most knowledgeable mem-
bers of the Academy on diagnosis-relat-
ed groups, gatekeepers, and physician 
reimbursement. He led strategy ses-
sions on how to inform and influence 
legislators and regulators regarding 
dermatologists’ unique contributions 
to patient care. Irwin was so effective 
as a committee member that he was 
appointed chairman. During his career, 
Irwin served on 16 Academy commit-
tees, councils, and task forces with a 
topic range from education and evalu-
ation to research.
In addition to his work for the 
Academy, this “organization man” held 
leadership positions in the Society for 
Investigative Dermatology, the American 
Board of Dermatology, the Association of 
Professors of Dermatology, the American 
Dermatology Association, the American 
Medical Association House of Delegates, 
and numerous advisory boards — and, 
of course, his real job as professor 
and chairman of the Department of 
Dermatology at New York University 
School of Medicine.
When Irwin was elected to the 
Board of Directors of the Academy he 
was what every director of an associa-
tion hopes for in a newly elected board 
member — knowledgeable, hardwork-
ing, attentive, responsive, and articu-
late. He studied the issues, asked ques-
tions, formed opinions, participated in 
debates, and had a positive influence on 
outcomes. He was respected by his col-
leagues on the board and was elected 
by them to the Executive Committee.
John Grupenhoff, consultant to the 
American Academy of Dermatology 
and the Society for Investigative 
Dermatology, 1975–2003:
Dr Irwin Freedberg played a unique 
role in dermatology and its interface 
with federal government activities from 
the middle 1970s.
While involved in governmen-
tal issues for the American Academy 
of Dermatology (he chaired the 
Government Relations Committee from 
1980 to 1982), he also played leader-
ship roles in the Society for Investigative 
Dermatology and in National Institutes 
of Health activities. He was president 
of the SID from 1981 to 1982 and had 
served on its board of directors earlier. 
He had a particular interest in research 
funding and regulatory issues. He 
served on councils for several of the 
National Institutes of Health, includ-
ing the National Institute of Allergy and 
Infectious Diseases (1977–1980), the 
National Cancer Institute (1983–1985), 
and the National Institute of Arthritis, 
Diabetes, and Digestive and Kidney 
Diseases (1985–1986).
Dr Freedberg fully understood the 
issues surrounding the congressio-
nal activities in 1987 to establish a 
separate National Institute of Arthritis 
and Musculoskeletal Diseases, which 
included skin research though its 
name did not reflect it. He worked 
with Dr Peyton Weary and other der-
matologists across the country to con-
vince Congress to include “Skin” in 
the Institute’s new name.
I especially enjoyed discussing with 
Irwin the politics of research, the per-
sonalities of members of Congress, 
and how the process was moving 
along, as well as the advocacy efforts 
that were ongoing. As can be seen 
from the sample above, the inter-
twined nature of his experiences has 
been invaluable to dermatology.
My last opportunity to work with 
Dr Freedberg was the “Burden of Skin 
Diseases” workshop in 2002 at the 
National Institutes of Health, which he 
chaired. The purpose of the meeting was 
to support, in a report on a congressional 
bill, language calling for evaluation of the 
economic impact of skin diseases as well 
as the emotional burdens they impose 
on patients and their families. At the 
meeting, I observed with considerable 
interest Dr Freedberg’s encouragement 
of the patient interest groups to outline 
their concerns to make sure they were 
fully discussed.
As many leaders of patient groups 
know, I regard them as the best advo-
cates for skin disease research in the 
federal government, especially in 
Congress. Dr Freedberg was a major 
advocate of patient groups and helped 
cement their relationship with derma-
tology organizations.
In summary, Irwin Freedberg contrib-
uted great leadership to the specialty of 
dermatology and to the organizations of 
which he was a member.
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Irwin M. Freedberg, MD, had an extraor-
dinary career in academic medicine. 
Others have focused on Irwin’s many 
contributions to research, education, 
and our professional organizations. I 
would like to focus, however, on Irwin’s 
interactions with the pharmaceutical 
industry. The relationship of academia 
and pharma has been at times a dif-
ficult one. As in many other aspects of 
dermatology, Irwin led the way in seek-
ing solutions and common ground that 
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